HCN2 cells were treated for 24h with paclitaxel (PTX, 50 nM), ixabepilone (50 nM), vincristine (VCR 25 nM, 50 nM and 100 nM), doxorubicin (DOX 400 ng/ml) and 5-fluorourocil (5-FU 5 mM). Immunoblots were hybridized with anti-tubulin (total α-tubulin and acetylated α-tubulin) and anti-p53 antibodies. Actin was used as a loading control.